Pipeline · Bill → Law
Step 1
Introduced
Jul 25, 2023
Step 2
Referred
Dec 17, 2024
E&C · Ways & Means
Step 3
Committee
Dec 6, 2023
Reported out
Step 4
House floor
Step 5
Senate
Step 6
Resolve Changes
Step 7
Signed
SummaryCRS Summary
This bill limits cost-sharing for covered drugs under the Medicare prescription drug benefit and Medicare Advantage. Specifically, for costs above the deductible but below the annual out-of-pocket threshold, the bill limits cost-sharing to the average net price of the drug (i.e., the average amount paid less any rebates) or the cash price (i.e., the price charged to an individual without insurance), whichever is lower. The Government Accountability Office must report on the bill's implementation.
Timeline · 10 actions
Dec 17, 2024
Referred to the Subcommittee on Health.
Dec 6, 2023
Committee Consideration and Mark-up Session Held
Dec 6, 2023
Ordered to be Reported (Amended) by the Yeas and Nays: 45 - 0.
Dec 5, 2023
Committee Consideration and Mark-up Session Held
Nov 15, 2023
Subcommittee Consideration and Mark-up Session Held
Nov 15, 2023
Forwarded by Subcommittee to Full Committee by Voice Vote.
Jul 28, 2023
Referred to the Subcommittee on Health.
Jul 25, 2023
Introduced in House
Jul 25, 2023
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Jul 25, 2023
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.